Asia Pacific Epigenetics Diagnostic Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2021 –2028 |
 Taille du marché (année de référence) |
USD 746.23 Million |
 Taille du marché (année de prévision) |
USD 2,767.57 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché du diagnostic épigénétique en Asie-Pacifique, par produit ( réactifs , kits, instruments et consommables, outils et enzymes bioinformatiques), technologie (méthylation de l'ADN, méthylation des histones, structures de chromatine, acétylation des histones, modification des grands ARN non codants et des microARN), type de thérapie (inhibiteurs de l'histone désacétylase (HDAC), inhibiteurs de l'ADN méthyltransférase (DNMT) et autres), application ( oncologie , maladies cardiovasculaires, maladies métaboliques , immunologie, maladies inflammatoires, maladies infectieuses et autres), utilisateur final (instituts universitaires et de recherche, sociétés pharmaceutiques et biotechnologiques , organismes de recherche sous contrat (CRO) et autres), canal de distribution (appels d'offres directs et ventes au détail), pays (Japon, Chine, Corée du Sud, Inde, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines, Vietnam, reste de l'Asie-Pacifique) Tendances de l'industrie et prévisions jusqu'en 2028.
Analyse et perspectives du marché : Marché du diagnostic épigénétique en Asie-Pacifique
Le marché du diagnostic épigénétique en Asie-Pacifique devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 18,3 % au cours de la période de prévision de 2021 à 2028 et devrait atteindre 2 767,57 millions USD d'ici 2028 contre 746,23 millions USD en 2020. La forte prévalence des maladies chroniques et le développement technologique dans le domaine de l'épigénétique seront probablement les principaux moteurs qui propulseront la demande du marché au cours de la période de prévision.
Le diagnostic épigénétique est l'étude de la génétique, des variations des traits cellulaires et physiques et de la biologie du développement causées par l'environnement externe. Cela affecte à son tour les gènes et la capacité cellulaire à lire les gènes sans être affecté par les changements de génotype. Les changements épigénétiques entraînent des changements dans le phénotype de l'organisme plutôt que dans le génotype, la séquence d'ADN et d'ARN sous-jacente restant inchangée. Les changements épigénétiques sont essentiels au développement car ils sont dynamiques et changent en fonction de l'environnement.
L'expression génétique des organismes est influencée par l'épigénétique, ce qui en fait le domaine le plus crucial de la biologie moléculaire et de la génétique du développement. Des organisations telles que le National Center Institute, le National Institute of Health et l'International Human Epigenome Consortium financent et soutiennent les activités de recherche et développement liées au domaine de l'épigénétique. L'épigénétique est également utilisée pour traiter diverses maladies chroniques telles que le cancer, les maladies métaboliques et autres.
Le rapport sur le marché du diagnostic épigénétique en Asie-Pacifique fournit des détails sur la part de marché, les nouveaux développements et l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste. Notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché du diagnostic épigénétique en Asie-Pacifique
Le marché du diagnostic épigénétique en Asie-Pacifique est classé en six segments notables qui sont basés sur le produit, la technologie, le type de thérapie, l'application, l'utilisateur final et le canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base des produits, le marché du diagnostic épigénétique de la région Asie-Pacifique est segmenté en réactifs, kits, instruments et consommables, outils bioinformatiques et enzymes. En 2021, le segment des réactifs devrait dominer le marché en raison de l'augmentation du nombre de lancements de produits de réactifs épigénétiques dans la région.
- Sur la base de la technologie, le marché du diagnostic épigénétique de la région Asie-Pacifique est segmenté en méthylation de l'ADN, méthylation des histones, structures de chromatine, acétylation des histones, grands ARN non codants et modification des microARN. En 2021, le segment de la méthylation de l'ADN devrait dominer le marché, car la technologie de méthylation de l'ADN est utilisée dans une variété de diagnostics épigénétiques de diverses maladies.
- En fonction du type de thérapie, le marché du diagnostic épigénétique de la région Asie-Pacifique est segmenté en inhibiteurs de l'histone désacétylase (HDAC), en inhibiteurs de l'ADN méthyltransférase (DNMT) et autres. En 2021, le segment des inhibiteurs de l'histone désacétylase (HDAC) devrait dominer le marché car il joue un rôle majeur dans plusieurs processus biologiques, tels que la prolifération, la progression du cycle cellulaire et la différenciation. L'histone désacétylase (HDAC) et ses inhibiteurs peuvent être utilisés pour modifier post-traductionnellement les histones, le code de l'histone qui est lu et reconnu par d'autres protéines pour réguler l'expression des gènes.
- En fonction des applications, le marché du diagnostic épigénétique de la région Asie-Pacifique est segmenté en oncologie, maladies cardiovasculaires, maladies métaboliques, immunologie, maladies inflammatoires et autres. En 2021, le segment de l'oncologie devrait dominer le marché en raison de la forte prévalence du cancer dans la région Asie-Pacifique.
- Sur la base de l'utilisateur final, le marché du diagnostic épigénétique de l'Asie-Pacifique est segmenté en instituts universitaires et de recherche, sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat (CRO) et autres. En 2021, le segment des instituts universitaires et de recherche devrait dominer le marché en raison de l'augmentation du financement des activités de recherche par des partenariats public-privé.
- On the basis of distribution channel, the Asia-Pacific epigenetics diagnostic market is segmented into direct tender and retail sales. In 2021, direct tender segment is expected to dominate the market due to escalation in marketing activities and improved customer services in Asia-Pacific region.
Asia-Pacific Epigenetics Diagnostic Market Country Level Analysis
Asia-Pacific epigenetics diagnostic market is analysed, and market size information is provided by country, product, technology, type of therapy, application, end user, and distribution channel.
The countries covered in the Asia-Pacific epigenetics diagnostic market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.
China is expected to dominate the market in Asia-Pacific, as the demand for epigenetics testing is increasing because of high prevalence of chronic diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in Asia-Pacific Epigenetics Diagnostic Market
Asia-Pacific epigenetics diagnostic market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the epigenetics diagnostic market. The data is available for the historic period 2010 to 2019.
Competitive Landscape and Asia-Pacific Epigenetics Diagnostic Market Share Analysis
Asia-Pacific epigenetics diagnostic market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to epigenetics diagnostic market.
Parmi les principales entreprises proposant des diagnostics épigénétiques, on trouve PerkinElmer Inc., Diagenode, F. Hoffman-La Roche Ltd, EPICYPHER, Promega Corporation, QIAGEN, Pacific Biosciences of California, Inc., Epigenomics AG, Reaction Biology, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Merck KGaA, Illumina, Inc., ACTIVEMOTIF, Thermo Fisher Scientific, Inc., EpiGentek Group Inc., Enzo Life Sciences, Inc., GlaxoSmithKline plc., MDxHealth, Abcam plc et Salarius Pharmaceuticals, Inc. Les analystes de DBMR comprennent les atouts de la concurrence et fournissent une analyse concurrentielle pour chaque concurrent séparément.
Les initiatives stratégiques des acteurs du marché et les nouvelles avancées technologiques en matière de diagnostic épigénétique comblent le fossé en matière de diversité des traitements.
Par exemple,
- En février 2020, Datar Cancer Genetics a annoncé sa participation à Apollo Cancer Conclave. Cela a aidé l'entreprise à fournir des informations correctes sur ses produits oncologiques sur le marché.
La collaboration, les coentreprises et d’autres stratégies des acteurs du marché améliorent le marché de l’entreprise sur le marché des instruments dentaires, ce qui offre également l’avantage à l’organisation d’améliorer son offre pour le marché du diagnostic épigénétique.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 REGULATIONS: ASIA PACIFIC EPIGENETICS DIAGNOSITC MARKET
5.1 UNITED STATES
5.1.1 ROLE OF FDA
5.1.2 ROLE OF CDC AND HCFA
5.2 EUROPEAN UNION
5.3 FRANCE
5.4 AUSTRALIA
5.5 SOUTH KOREA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CANCER
6.1.2 INCREASE IN ASIA PACIFIC GERIATRIC POPULATION
6.1.3 RISE IN RESEARCH & DEVELOPMENT (R&D) ACTIVITIES IN THE FIELD OF EPIGENETICS
6.1.4 PRESENCE OF ADVANCED TECHNOLOGIES TO IMPROVE DIAGNOSTIC EFFICIENCY
6.1.5 IMPROVING HEALTHCARE FACILITIES
6.2 RESTRAINTS
6.2.1 INADEQUACY IN IDENTIFICATION AND VALIDATION OF BIOMARKERS
6.2.2 HIGH COST OF EPIGENETICS DIAGNOSTIC EQUIPMENT
6.3 OPPORTUNITIES
6.3.1 WIDE RANGE OF APPLICATION
6.3.2 PROMOTER METHYLATION IN DIFFERENT TYPES OF CANCER
6.3.3 EMERGING MARKETS
6.3.4 INCREASING HEALTHCARE EXPENDITURE
6.3.5 RISING PER CAPITA INCOME
6.4 CHALLENGES
6.4.1 ESCALATING PRODUCT RECALL
6.4.2 SHORTAGE OF SKILLED PERSONNEL
6.4.3 EMERGENCE OF COVID-19
6.4.4 LACK OF ACCESSIBILITY
7 COVID-19 IMPACT ON ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID 19
7.5 CONCLUSION:
8 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 REAGENTS
8.2.1 ANTIBODIES
8.2.2 BUFFERS
8.2.3 HISTONES
8.2.4 MAGNETIC BEADS
8.2.5 PRIMERS
8.2.6 OTHERS
8.3 KITS
8.3.1 CHIP SEQUENCING KIT
8.3.2 WHOLE GENOMIC AMPLIFICATION KIT
8.3.3 BISULFITE CONVERSION KIT
8.3.4 5-HMC & 5-MC ANALYSIS KITS
8.3.5 RNA SEQUENCING KIT
8.3.6 OTHERS
8.4 INSTRUMENTS & CONSUMABLES
8.4.1 NEXT-GENERATION SEQUENCERS
8.4.2 QPCR
8.4.3 MASS SPECTROMETERS
8.4.4 SONICATORS
8.4.5 OTHERS
8.5 BIOINFORMATICS TOOLS
8.6 ENZYMES
8.6.1 DNA-MODIFYING ENZYMES
8.6.2 PROTEIN-MODIFYING ENZYMES
8.6.3 RNA-MODIFYING ENZYMES
8.6.4 OTHERS
9 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 DNA METHYLATION
9.2.1 REAGENTS
9.2.2 KITS
9.2.3 INSTRUMENTS & CONSUMABLES
9.2.4 ENZYMES
9.3 HISTONE METHYLATION
9.3.1 REAGENTS
9.3.2 KITS
9.3.3 INSTRUMENTS & CONSUMABLES
9.3.4 ENZYMES
9.4 HISTONE ACETYLATION
9.4.1 REAGENTS
9.4.2 KITS
9.4.3 INSTRUMENTS & CONSUMABLES
9.4.4 ENZYMES
9.5 LARGE NON-CODING RNA
9.5.1 REAGENTS
9.5.2 KITS
9.5.3 INSTRUMENTS & CONSUMABLES
9.5.4 ENZYMES
9.6 MICRORNA MODIFICATION
9.6.1 REAGENTS
9.6.2 KITS
9.6.3 INSTRUMENTS & CONSUMABLES
9.6.4 ENZYMES
9.7 CHROMATIN STRUCTURES
9.7.1 REAGENTS
9.7.2 KITS
9.7.3 INSTRUMENTS & CONSUMABLES
9.7.4 ENZYMES
10 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY
10.1 OVERVIEW
10.2 HISTONE DEACETYLASE (HDAC) INHIBITORS
10.3 DNA METHYLTRANSFERASE (DNMT) INHIBITORS
10.4 OTHERS
11 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.2.1 SOLID TUMORS
11.2.2 LIQUID TUMORS
11.3 CARDIOVASCULAR DISEASES
11.4 METABOLIC DISEASES
11.4.1 METABOLIC SYNDROME
11.4.2 TYPE 2 DIABETES (T2D)
11.4.3 OTHERS
11.5 IMMUNOLOGY
11.6 INFLAMMATORY DISEASES
11.7 INFECTIOUS DISEASES
11.8 OTHERS
12 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 ACADEMIC AND RESEARCH INSTITUTES
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
12.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
12.5 OTHERS
13 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY REGION
14.1 ASIA-PACIFIC
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 AUSTRALIA
14.1.5 SOUTH KOREA
14.1.6 SINGAPORE
14.1.7 MALAYSIA
14.1.8 THAILAND
14.1.9 INDONESIA
14.1.10 PHILIPPINES
14.1.11 REST OF ASIA-PACIFIC
15 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ILLUMINA, INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 MERCK KGAA
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 BIO-RAD LABORATORIES, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F. HOFFMANN-LA ROCHE LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 RECENT FINANCIALS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 AGILENT TECHNOLOGIES, INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 PERKINELMER INC
17.7.1 COMPANY SNAPSHOT
17.7.2 RECENT FINANCIALS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 QIAGEN
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 ABCAM PLC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 ACTIVEMOTIF
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 BLUESTAR GENOMICS INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 CAMBRIDGE EPIGENETIX (CEGX)
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 DATAR CANCER GENETICS
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 DIAGENODE
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 ECLIPSE BIOINNOVATIONS
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ENZO LIFE SCIENCES, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 EPICYPHER
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENTS
17.18 EPIGENOMICS AG
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 EPIGENTEK GROUP INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 EPIZYME, INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 GLAXOSMITHKLINE PLC.
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 MDXHEALTH
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 MNEMO
17.23.1 COMPANY SNAPSHOT
17.23.2 PRODUCT PORTFOLIO
17.23.3 RECENT DEVELOPMENT
17.24 NEW ENGLAND BIOLABS
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
17.25 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
17.25.1 COMPANY SNAPSHOT
17.25.2 RECENT FINANCIALS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENTS
17.26 PROMEGA CORPORATION
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
17.27 REACTION BIOLOGY
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
17.28 SALARIUS PHARMACEUTICALS, INC.
17.28.1 COMPANY SNAPSHOT
17.28.2 RECENT FINANCIALS
17.28.3 PRODUCT PORTFOLIO
17.28.4 RECENT DEVELOPMENTS
17.29 ZYMO RESEARCH CORPORATION
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 HEALTH CARE FACILITIES
TABLE 2 PER CAPITA AMOUNTS: UNITED STATES (1960–2017 YEARS)
TABLE 3 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 4 ASIA PACIFIC REAGENTS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA PACIFIC REAGENTS IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 6 ASIA PACIFIC KITS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA PACIFIC KITS IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 8 ASIA PACIFIC INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 ASIA PACIFIC INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 10 ASIA PACIFIC BIOINFORMATICS TOOLS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA PACIFIC ENZYMES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 ASIA PACIFIC ENZYMES IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 13 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 14 ASIA PACIFIC DNA METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 ASIA PACIFIC DNA METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 16 ASIA PACIFIC HISTONE METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA PACIFIC HISTONE METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 18 ASIA PACIFIC HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA PACIFIC HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 20 ASIA PACIFIC LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA PACIFIC LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 24 ASIA PACIFIC CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA PACIFIC CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 26 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC HISTONE DEACETYLASE (HDAC) INHIBITORS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA PACIFIC DNA METHYLTRANSFERASE (DNMT) INHIBITORS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 ASIA PACIFIC OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 31 ASIA PACIFIC ONCOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC ONCOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 33 ASIA PACIFIC CARDIOVASCULAR DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC METABOLIC DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC METABOLIC DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC IMMUNOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC INFLAMMATORY DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 ASIA PACIFIC INFECTIOUS DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 ASIA PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFIC CONTRACT RESEARCH ORGANIZATIONS (CROS) IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 ASIA PACIFIC OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 ASIA PACIFIC DIRECT TENDER IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 ASIA PACIFIC RETAIL SALES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 64 ASIA-PACIFIC METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 65 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 66 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 CHINA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 68 CHINA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 69 CHINA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 70 CHINA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 71 CHINA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 72 CHINA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 CHINA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 CHINA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 CHINA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 76 CHINA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 77 CHINA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 78 CHINA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 79 CHINA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 80 CHINA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 81 CHINA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 82 CHINA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 83 CHINA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 CHINA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 JAPAN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 86 JAPAN REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 87 JAPAN KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 88 JAPAN INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 89 JAPAN ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 90 JAPAN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 91 JAPAN DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 92 JAPAN HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 93 JAPAN HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 94 JAPAN LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 95 JAPAN MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 96 JAPAN CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 97 JAPAN EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 98 JAPAN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 99 JAPAN ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 100 JAPAN METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 101 JAPAN EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 102 JAPAN EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 103 INDIA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 104 INDIA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 105 INDIA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 106 INDIA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 107 INDIA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 108 INDIA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 109 INDIA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 110 INDIA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 111 INDIA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 112 INDIA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 113 INDIA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 114 INDIA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 115 INDIA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 116 INDIA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 117 INDIA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 118 INDIA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 119 INDIA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 120 INDIA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 121 AUSTRALIA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 122 AUSTRALIA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 123 AUSTRALIA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 124 AUSTRALIA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 125 AUSTRALIA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 126 AUSTRALIA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 127 AUSTRALIA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 128 AUSTRALIA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 129 AUSTRALIA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 130 AUSTRALIA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 131 AUSTRALIA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 132 AUSTRALIA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 133 AUSTRALIA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 134 AUSTRALIA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 135 AUSTRALIA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 136 AUSTRALIA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 137 AUSTRALIA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 138 AUSTRALIA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 139 SOUTH KOREA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 140 SOUTH KOREA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 141 SOUTH KOREA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 142 SOUTH KOREA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 143 SOUTH KOREA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 144 SOUTH KOREA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 145 SOUTH KOREA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 146 SOUTH KOREA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 147 SOUTH KOREA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 148 SOUTH KOREA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 149 SOUTH KOREA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 150 SOUTH KOREA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 151 SOUTH KOREA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 152 SOUTH KOREA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 153 SOUTH KOREA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 154 SOUTH KOREA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 155 SOUTH KOREA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 156 SOUTH KOREA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 157 SINGAPORE EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 158 SINGAPORE REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 159 SINGAPORE KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 160 SINGAPORE INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 161 SINGAPORE ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 162 SINGAPORE EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 163 SINGAPORE DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 164 SINGAPORE HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 165 SINGAPORE HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 166 SINGAPORE LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 167 SINGAPORE MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 168 SINGAPORE CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 169 SINGAPORE EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 170 SINGAPORE EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 171 SINGAPORE ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 172 SINGAPORE METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 173 SINGAPORE EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 174 SINGAPORE EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 175 MALAYSIA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 176 MALAYSIA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 177 MALAYSIA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 178 MALAYSIA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 179 MALAYSIA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 180 MALAYSIA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 181 MALAYSIA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 182 MALAYSIA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 183 MALAYSIA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 184 MALAYSIA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 185 MALAYSIA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 186 MALAYSIA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 187 MALAYSIA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 188 MALAYSIA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 189 MALAYSIA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 190 MALAYSIA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 191 MALAYSIA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 192 MALAYSIA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 193 THAILAND EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 194 THAILAND REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 195 THAILAND KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 196 THAILAND INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 197 THAILAND ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 198 THAILAND EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 199 THAILAND DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 200 THAILAND HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 201 THAILAND HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 202 THAILAND LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 203 THAILAND MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 204 THAILAND CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 205 THAILAND EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 206 THAILAND EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 207 THAILAND ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 208 THAILAND METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 209 THAILAND EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 210 THAILAND EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 211 INDONESIA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 212 INDONESIA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 213 INDONESIA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 214 INDONESIA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 215 INDONESIA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 216 INDONESIA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 217 INDONESIA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 218 INDONESIA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 219 INDONESIA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 220 INDONESIA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 221 INDONESIA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 222 INDONESIA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 223 INDONESIA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 224 INDONESIA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 225 INDONESIA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 226 INDONESIA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 227 INDONESIA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 228 INDONESIA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 229 PHILIPPINES EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 230 PHILIPPINES REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 231 PHILIPPINES KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 232 PHILIPPINES INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 233 PHILIPPINES ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 234 PHILIPPINES EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 235 PHILIPPINES DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 236 PHILIPPINES HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 237 PHILIPPINES HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 238 PHILIPPINES LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 239 PHILIPPINES MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 240 PHILIPPINES CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 241 PHILIPPINES EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 242 PHILIPPINES EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 243 PHILIPPINES ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 244 PHILIPPINES METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 245 PHILIPPINES EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 246 PHILIPPINES EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 247 REST OF ASIA-PACIFIC EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Liste des figures
FIGURE 1 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET
FIGURE 15 EPIGENETIC REGULATION IN CANCER
FIGURE 16 PREVALENCE OF CANCER WORLDWIDE
FIGURE 17 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES WORLDWIDE
FIGURE 18 NORTH AMERICA AGING POPULATION (IN MILLIONS)
FIGURE 19 GERIATRIC POPULATION WORLWIDE
FIGURE 20 NCI FUNDING FOR CANCER RESEARCH
FIGURE 21 EPIGENETIC IVD TESTS
FIGURE 22 THREE NEXT GENERATION SEQUENCING PLATFORMS
FIGURE 23 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, 2020
FIGURE 24 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 25 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 26 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, 2020
FIGURE 28 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)
FIGURE 29 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2021-2028)
FIGURE 30 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, 2020
FIGURE 32 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, 2021-2028 (USD MILLION)
FIGURE 33 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, CAGR (2021-2028)
FIGURE 34 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, 2020
FIGURE 36 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 37 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 38 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 39 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY END USER, 2020
FIGURE 40 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 41 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY END USER, CAGR (2021-2028)
FIGURE 42 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 45 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 46 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET: SNAPSHOT (2020)
FIGURE 48 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2020)
FIGURE 49 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 ASIA-PACIFIC EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT (2021-2028)
FIGURE 52 ASIA PACIFIC EPIGENETICS DIAGNOSTIC MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
